tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Sean Laaman, 2 are a HOLD (33.33%), 4 are a BUY (66.67%).
Analyst Sean Laaman, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 100% that have a potential upside of 13.82% achieved within 67 days.
Sean Laaman’s has documented 11 price targets and ratings displayed on 1 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on RMD, ResMed at 25-Jan-2024.
Analyst best performing recommendations are on RMD (RESMED).
The best stock recommendation documented was for RMD (RESMED) at 6/17/2020. The price target of $176 was fulfilled within 6 days with a profit of $9.23 (5.53%) receiving and performance score of 9.22.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
28 days ago
(25-Oct-2024)
11/11 (100%)
$-8.75 (-3.58%)
211
Buy
$270
$35.26 (15.02%)
$220
1 months 27 days ago
(26-Sep-2024)
7/9 (77.78%)
$27.44 (11.31%)
154
Hold
$200
4 months 28 days ago
(25-Jun-2024)
7/12 (58.33%)
$-17.58 (-8.08%)
84
Buy
$215
$-19.74 (-8.41%)
$215
7 months 26 days ago
(27-Mar-2024)
10/11 (90.91%)
$19.11 (9.76%)
114
$164
$-70.74 (-30.14%)
$158
9 months 28 days ago
(25-Jan-2024)
5/6 (83.33%)
$-21.47 (-11.58%)
162
What Year was the first public recommendation made by Sean Laaman?
